An observational study in Renal Cell Carcinoma, Renal Cell Cancer and Adenocarcinoma Of Kidney, sponsored by Bristol-Myers Squibb. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by Bristol-Myers Squibb · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb — 5 open to participants now, 8 under way, 2 of them phase 3. Carcinoma, Renal Cell · Bristol-Myers Squibb.
Among the 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb, this one is one of 3 that started in 2018, is one of 9 observational ones, and was the 25th registered.
2,041 studies on the registry are indexed under Carcinoma, Renal Cell; 397 are open to participants now.
Browse Carcinoma, Renal Cell studies →5 of the 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
Bristol-Myers Squibb · Sites in United States, Canada, France and 2 more countries
Ages 18+
Bristol-Myers Squibb · Sites in United States, Australia, Canada
Ages 18+
Bristol-Myers Squibb · Sites in United States, Australia, Canada and 5 more countries
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Belgium, France and 4 more countries
Ages 18+
By country, each count listing its studies:
Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 12 · Phase 3 6 · Phase 4 2
First in 2003; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 623 is above the median of 153 across 338 observational studies indexed under Carcinoma, Renal Cell.
Median enrollment 119 across the 33 interventional studies, 297 across the 9 observational. Of the 32 that completed or were terminated, 16 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
2 of the studies in Carcinoma, Renal Cell by Bristol-Myers Squibb that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03873402Phase 3Bristol-Myers SquibbA Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | 2027-03-11 |
| NCT06764771Bristol-Myers SquibbA Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors | 2027-10-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a French, nationwide, prospective, observational, multi-center study in participants diagnosed with advanced renal cell carcinoma, who start a new systemic therapy with nivolumab with or without ipilimumab for the first time and within the market authorization approval.
Adult participants who are at least 18 of age at the time of the treatment decision with the diagnosis of advanced renal cell cancer (RCC) (histologically or cytologically confirmed) and whose physician has already decided to initiate a treatment with nivolumab or with nivolumab plus ipilimumab for the first time for the treatment of RCC, according to the label approved in France.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-Adult participants with the diagnosis of advanced renal cell cancer (RCC) (histologically or cytologically) whose physician has already decided to initiate a treatment with nivolumab with or without ipilimumab for the first time for the treatment of RCC, according to the label approved in France
NOTE: Nivolumab with ipilimumab is indicated for the treatment of adult participants with intermediate/poor-risk advanced RCC
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants diagnosed with advanced renal cell carcinoma (RCC) and whose physician has decided to initiate a treatment with Nivolumab for the first time for the treatment of RCC
Participants diagnosed with advanced RCC and whose physician has decided to start a new systemic therapy with nivolumab + ipilimumab for the first time for the treatment of RCC
This study also gives Nivolumab, Ipilimumab. No intervention listed here names it: that was found by reading the record.
Overall Survival (OS)
By Cohort
Time frame: Up to 3 years
Overall Survival (OS)
Time frame: Up to 3 years
Progression Free Survival (PFS)
Time frame: Up to 3 years
Overall Response Rate (ORR)
Time frame: Up to 3 years
Best Overall Response Rate (BORR)
Time frame: Up to 3 years
Best Overall Response (BOR)
Time frame: Up to 3 years
Distribution of socio-demographic characteristics of participants
Time frame: Approximately 3 years
Distribution of clinical characteristics of participants
Time frame: Approximately 3 years
Distribution of management of participants with treatment-related adverse events (AEs)
Time frame: Approximately 3 years
Distribution of management of participants according to Memorial Sloan Kettering Cancer Center (MSKCC) score
Time frame: At baseline
Distribution of management of participants according to International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score
Time frame: At baseline
Distribution of treatment patterns in participants with advanced Renal Cell Carcinoma (RCC)
Time frame: Approximately 3 years
Distribution of incidence of AEs
Time frame: Approximately 3 years
Distribution of Severity of AEs
Time frame: Approximately 3 years
Distribution of management of AEs
Time frame: Approximately 3 years
Health-related quality of life of participants using Functional Assessment of Cancer Therapy -Kidney Symptom Index (FKSI-19) questionnaires
The FKSI-19 will be graded by the patient on a scale from 0 to 4 (range "not at all to very much")
Time frame: Approximately 3 years
Health-related quality of life of participants using European Quality of Life-5 Dimensions (EQ-5D) questionnaires
The EQ-5D descriptive system consists of 5 dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression, each with 3 levels (eg, no problems, moderate problems, extreme problems)
Time frame: Approximately 3 years
Plan to share: No
Ran from Jan 2018 to primary completion in Dec 2025, 94 months.
Of 42 industry-sponsored observational studies under Carcinoma, Renal Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 91. This study's 94 months is above that.
Counting every sponsor, half of 139 studies reached it within 50 months; a quarter within 33 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.